Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension

Hypertension

Volumn 63, Issue 5, 2014, Pages 991-999

  Fadl Elmula, Fadl Elmula M ^a,b   Hoffmann, Pavel ^a   Larstorp, Anne C ^a   Fossum, Eigil ^a   Brekke, Magne ^a   Kjeldsen, Sverre E ^a,b   Gjønnæss, Eyvind ^a   Hjørnholm, Ulla ^a   Kjær, Vibeke N ^a   Rostrup, Morten ^a   Os, Ingrid ^a,b   Stenehjem, Aud ^a   Høieggen, Aud ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Blood pressure; Drug therapy; Hypertension

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; MINOXIDIL; MOXONIDINE; RENIN INHIBITOR; SPIRONOLACTONE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BRADYCARDIA; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEMATOMA; HUMAN; HYPOTENSION; KIDNEY DENERVATION; MALE; MAXIMUM TOLERATED DOSE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RENAL SYMPATHETIC DENERVATION; RESEARCH ETHICS; SEXUAL DYSFUNCTION; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESISTANT DEPRESSION; URINARY CATHETER;

BLOOD PRESSURE; DRUG THERAPY; HYPERTENSION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; OFFICE VISITS; PROSPECTIVE STUDIES; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84902265655     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03246     Document Type: Article

References (48)

1. de la Sierra A, Segura J, Banegas Jr, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57: 889-890.
2. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376: 1903-1909.
3. Gifford RW. An algorithm for the management of resistant hypertension. Hypertension. 1988; 11: 171-175.
4. Klein LE. Compliance and blood pressure control. Hypertension. 1988; 11(3 Pt 2):II61-II64.
5. Grossman E. Ambulatory blood pressure monitoring in the diagnosis and management of hypertension. Diabetes Care. 2013; 36(SUPPL. 2):S307-S311.
6. Templin C, Jaguszewski M, Ghadri J.R., Sudano I., Gaehwiler R, Hellermann JP, Schoenenberger-Berzins R, Landmesser U., Erne P, Noll G, Lüscher TF. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity catheter system and the EnligHTN multi-electrode renal dener-vation catheter. Eur Heart J. 2013; 34: 2141-2148, 2148b.
7. Fadl Elmula F.E., Hoffmann P, Fossum E., Brekke M, Gjønnæss E, Hjørnholm U, Kjær VN, Rostrup M, Kjeldsen SE, Os I, Stenehjem AE, Høieggen A. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013; 62: 526-532.
8. Taler SJ, Textor SC, Augustine JE Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002; 39: 982-988. (Pubitemid 34547797)
9. Faini A, Omboni S, Tifrea M., Bubenek S, Lazar O, Parati G. Cardiac index assessment: validation of a new non-invasive very low current thoracic bio-impedance device by thermodilution. Blood Press. 2014. In press.
10. Abdelhammed AI, Smith RD, Levy P, Smits G.J., Ferrario CM Noninvasive hemodynamic profiles in hypertensive subjects. Am J Hypertens. 2005; 18(2 Pt 2): 51S-59S. (Pubitemid 40332565)
11. Sanford T, Treister N, Peters C. Use of noninvasive hemodynamics in hypertension management. Am J Hypertens. 2005; 18(2 Pt 2): 87S-91S. (Pubitemid 40332570)
12. Treister N, Wagner K, Jansen PR Reproducibility of impedance cardi-ography parameters in outpatients with clinically stable coronary artery disease. Am J Hypertens. 2005; 18(2 Pt 2): 44S-50S. (Pubitemid 40332564)
13. Ventura HO, Taler SJ, Strobeck JE Hypertension as a hemodynamic disease: the role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. Am J Hypertens. 2005; 18(2 Pt 2): 26S-43S. (Pubitemid 40332563)
14. Smith RD, Levy P, Ferrario CM Consideration of noninvasive hemody-namic monitoring to target reduction of blood pressure levels study group. Hypertension. 2006; 47: 771-777.
15. Ferrario CM, Flack JM, Strobeck J.E., Smits G., Peters C. Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials. Ther Adv Cardiovasc Dis. 2010; 4: 5-16.
16. Krzesiński P., Gielerak GG, Kowal JJ A "patient- tailored" treatment of hypertension with use of impedance cardiography: a randomized, prospective and controlled trial. Med Sci Monit. 2013; 19: 242-250.
17. Ceral J, Habrdova V, Vorisek V., Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011; 34: 87-90.
18. Kandzari DE, Bhatt DL, Sobotka P.A., O'Neill WW, Esler M, Flack J.M., Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012; 35: 528-535.
19. Persu A, Jin Y, Azizi M., Baelen M, et al.; on behalf of the European Network Coordinating research on REnal denervation (ENCOReD). Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014; 28: 150-156.
20. Os I, Kjeldsen SE, Westheim A, Jackson M.B., Akesson I., Frederichsen P, Eide I, Leren P. The effect of sodium depletion and potassium supplementation on vasopressin, renin and catecholamines in hypertensive men. Acta Med Scand. 1986; 220: 195-203. (Pubitemid 17168525)
21. Beckmann SL, Os I, Kjeldsen S.E., Eide IK, Westheim AS, Hjermann I. Effect of dietary counselling on blood pressure and arterial plasma cat-echolamines in primary hypertension. Am J Hypertens. 1995; 8: 704-711.
22. Davis MI, Filion KB, Zhang D, Eisenberg M.J., Afilalo J., Schiffrin EL, Joyal D. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol. 2013; 62: 231-241.
23. Pokushalov E, Romanov A, Corbucci G., Artyomenko S, Baranova V, Turov A., Shirokova N, Karaskov A, Mittal S, Steinberg JS. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012; 60: 1163-1170.
24. Jin Y, Thijs L, Persu A., Kjeldsen S, Staessen JA Letter to the Editor: no support for renal denervation in a meta-analysis. J Am Coll Cardiol. 2013; 62: 2029-2030.
25. Staessen JA, Jin Y, Thijs L., Persu A, Azizi M, Kjeldsen S. Letter to the Editor: first-in-man randomized clinical trial of renal denervation for atrial arrhythmia raises concern. J Am Coll Cardiol. 2013; 62:e445-e448.
26. Brinkmann J, Heusser K, Schmidt B.M., Menne J., Klein G, Bauersachs J, Haller H., Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2012; 60: 1485-1490.
27. Mahfoud F, Kjeldsen SE, Daemen J. Resistant hypertension treatments - a new area in interventional treatments. EuroIntervention. 2013; 9(Suppl R):R7-R160.
28. Hansson L, Zanchetti A, Carruthers S.G., Dahlöf B, Elmfeldt D., Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351: 1755-1762. (Pubitemid 28269185)
29. Bramley TJ, Gerbino PP, Nightengale B.S., Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006; 12: 239-245. (Pubitemid 47400613)
30. Savard S, Frank M, Bobrie G., Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J Am Coll Cardiol. 2012; 60: 2422-2424.
31. Verloop WL, Vink EE, Voskuil M, Vonken E.J., Rookmaaker MB, Bots ML, Doevendans PA, Blankestijn P.J., Spiering W. Eligibility for percutaneous renal denervation: the importance of a systematic screening. J Hypertens. 2013; 31: 1662-1668.
32. Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwib́ski P, Bieleb́ P, Klisiewicz A, Michałowska I, Warchoł E, Januszewicz M, Kała M, Witkowski A, Wiȩcek A, Narkiewicz K, Somers VK, Januszewicz A. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens. 2013; 27: 678-685.
33. Egan BM, Zhao Y, Axon R.N., Brzezinski WA, Ferdinand KC Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011; 124: 1046-1058.
34. Stenehjem AE, Os I. Reproducibility of blood pressure variability, white-coat effect and dipping pattern in untreated, uncomplicated and newly diagnosed essential hypertension. Blood Press. 2004; 13: 214-224. (Pubitemid 39248184)
35. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic dener-vation for resistant hypertension: durability of blood pressure reduction out to 24 months Hypertension. 2011; 57: 911-917.
36. Persu A, Renkin J, Thijs L., Staessen JA Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012; 60: 596-606.
37. Vonend O, Antoch G, Rump L.C., Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012; 380: 778.
38. Persu A, Azizi M, Burnier M., Staessen JA Residual effect of renal denervation in patients with truly resistant hypertension. Hypertension. 2013; 62: 450-452.
39. Oparil S, Narkiewicz K, Kjeldsen S., Hedner T. Renal nerve ablation: emerging role in therapeutics. Blood Press. 2011; 20: 253-255.
40. Mahfoud F, Kjeldsen SE Cather-based renal denervation: a word of caution. EuroIntervention. 2013; 8: 997-998.
41. Kjeldsen SE, Os I, Mahfoud F. Treatment resistant hypertension and renal sympathetic denervation: drug adherence and the consolidation of blood pressure lowering effects. EuroIntervention. 2013; 9(Suppl R):R7-R9.
42. Kjeldsen SE, Narkiewicz K, Oparil S., Hedner T. Blood pressure lowering effect of renal sympathetic denervation or placebo?-building expectations for Symplicity-HTN 3. Blood Press. 2013; 22: 279-281.
43. Schmieder RE, Redon J, Grassi G., Kjeldsen SE, Mancia G, Narkiewicz K, Parati G., Ruilope L, van de Borne P, Tsioufis C. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens. 2012; 30: 837-841.
44. Schmieder RE, Redon J, Grassi G., Kjeldsen SE, Mancia G, Narkiewicz K, Parati G., Ruilope L, van de Borne P, Tsioufis C. Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention. 2013; 9(Suppl R):R58-R66.
45. Schlaich MP, Schmieder RE, Bakris G, et al International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013; 62: 2031-2045.
46. Schmieder RE, Grassi G, Kjeldsen SE Patients with treatment-resistant hypertension report increased stress and anxiety: a worldwide study. J Hypertens. 2013; 31: 610-615.
47. Krum H, Schlaich MP, Sobotka P.A., Böhm M, Mahfoud F., Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014; 383: 622-629.
48. Jung O, Gechter JL, Wunder C, Paulke A., Bartel C, Geiger H, Toennes SW Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013; 31: 766-774.